Alembic Pharmaceuticals announced that its joint venture, Aleor Dermaceuticals, has got the final nod from the US health regulator Food & Drug Administration (FDA) for its Nystatin and Triamcinolone Acetonide ointment, which is used for the treatment of cutaneous candidiasis. Cutaneous candidiasis is an infection of the skin and nails caused by the candida fungus.

The approval is for the 100,000 units/grams of Nystatin and Triamcinolone Acetonide Ointment, Alembic Pharmaceuticals said in a regulatory filing. The company further said that it had been proved that the nystatin-steroid combination gives more significant benefits than the nystatin component alone during the first few days of treatment.